Pith. sign in

REVIEW 15 cited by

TxAgent: An AI Agent for Therapeutic Reasoning Across a Universe of Tools

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2503.10970 v1 pith:TP67EP2B submitted 2025-03-14 cs.AI cs.LG

TxAgent: An AI Agent for Therapeutic Reasoning Across a Universe of Tools

classification cs.AI cs.LG
keywords reasoningtreatmenttxagentacrossclinicaldrugtoolsdrugs
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
read the original abstract

Precision therapeutics require multimodal adaptive models that generate personalized treatment recommendations. We introduce TxAgent, an AI agent that leverages multi-step reasoning and real-time biomedical knowledge retrieval across a toolbox of 211 tools to analyze drug interactions, contraindications, and patient-specific treatment strategies. TxAgent evaluates how drugs interact at molecular, pharmacokinetic, and clinical levels, identifies contraindications based on patient comorbidities and concurrent medications, and tailors treatment strategies to individual patient characteristics. It retrieves and synthesizes evidence from multiple biomedical sources, assesses interactions between drugs and patient conditions, and refines treatment recommendations through iterative reasoning. It selects tools based on task objectives and executes structured function calls to solve therapeutic tasks that require clinical reasoning and cross-source validation. The ToolUniverse consolidates 211 tools from trusted sources, including all US FDA-approved drugs since 1939 and validated clinical insights from Open Targets. TxAgent outperforms leading LLMs, tool-use models, and reasoning agents across five new benchmarks: DrugPC, BrandPC, GenericPC, TreatmentPC, and DescriptionPC, covering 3,168 drug reasoning tasks and 456 personalized treatment scenarios. It achieves 92.1% accuracy in open-ended drug reasoning tasks, surpassing GPT-4o and outperforming DeepSeek-R1 (671B) in structured multi-step reasoning. TxAgent generalizes across drug name variants and descriptions. By integrating multi-step inference, real-time knowledge grounding, and tool-assisted decision-making, TxAgent ensures that treatment recommendations align with established clinical guidelines and real-world evidence, reducing the risk of adverse events and improving therapeutic decision-making.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Forward citations

Cited by 15 Pith papers

Reviewed papers in the Pith corpus that reference this work. Sorted by Pith novelty score.

  1. The limits of bio-molecular modeling with large language models : a cross-scale evaluation

    cs.LG 2026-04 unverdicted novelty 7.0

    LLMs perform adequately on bio-molecular classification tasks but remain weak on regression, with hybrid architectures outperforming others on long sequences and fine-tuning hurting generalization.

  2. Evidence-Grounded AI for Musculoskeletal Care

    cs.AI 2026-07 unverdicted novelty 6.0

    OrthoPilot, an LLM clinical system integrating live hospital data and external knowledge, reportedly beat 25-year orthopaedic experts and raised full-chain management success and bed throughput in multi-site studies.

  3. Evidence-Grounded AI for Musculoskeletal Care

    cs.AI 2026-07 conditional novelty 6.0

    OrthoPilot, an LLM agent that retrieves hospital and external evidence, outperformed 81 orthopedic physicians in retrospective testing and raised full-chain management success by 10.6 percentage points in a 1,870-case...

  4. Aligning Clinical Needs and AI Capabilities: A Survey on LLMs for Medical Reasoning

    cs.AI 2026-07 accept novelty 6.0

    A dual clinical-computational taxonomy for medical LLM reasoning plus a five-level 5k-sample benchmark showing specialists excel at diagnosis and general models at decision support/dialogue.

  5. DrugClaw and DrugAudit: A Primary-Source-Grounded Agent and Authority-Aware Benchmark for Drug-Information Question Answering

    cs.CL 2026-05 unverdicted novelty 6.0

    DrugClaw tops benchmarks on primary-source grounding and faithfulness for drug-information QA while DrugAudit provides an authority-aware evaluation set of 3,772 items.

  6. AutoScientists: Self-Organizing Agent Teams for Long-Running Scientific Experimentation

    cs.AI 2026-05 unverdicted novelty 6.0

    Decentralized AI agent teams self-organize around hypotheses, critique proposals, and share knowledge to outperform single-agent baselines on biomedical ML, language-model optimization, and protein fitness tasks.

  7. Large Language Models Meet Biomedical Knowledge Graphs for Mechanistically Grounded Therapeutic Prioritization

    cs.AI 2026-04 unverdicted novelty 6.0

    DrugKLM integrates knowledge graphs and LLMs to prioritize mechanistically plausible drug repurposing candidates, outperforming baselines and aligning scores with improved survival signatures in cancer data.

  8. MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization

    cs.AI 2026-04 unverdicted novelty 6.0

    MolClaw deploys a hierarchical skill system (tool, workflow, and discipline levels) to achieve state-of-the-art results on MolBench tasks requiring 8 to 50+ sequential tool calls in drug discovery.

  9. EMBL AI Librarian: Life-Sciences Knowledge Layer for AI Agents

    cs.CL 2026-07 accept novelty 5.5

    A single LLM orchestrates Europe PMC subquery planning, BM25 paragraph ranking, and evidence filtering, improving life-science agent performance on four benchmark suites without maintaining a dense literature index.

  10. Evaluating Agentic Bioinformatics through Function, Evidence, and Validation

    cs.AI 2026-07 conditional novelty 5.0

    Agentic bioinformatics systems mostly demonstrate planning and tool execution but rarely prospective empirical validation, so the paper argues evaluation should center on inspectable workflow trajectories (FEV) rather...

  11. Externalization in LLM Agents: A Unified Review of Memory, Skills, Protocols and Harness Engineering

    cs.SE 2026-04 accept novelty 5.0

    LLM agent progress depends on externalizing cognitive functions into memory, skills, protocols, and harness engineering that coordinates them reliably.

  12. MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization

    cs.AI 2026-04 unverdicted novelty 5.0

    MolClaw deploys a hierarchical skill architecture to reach state-of-the-art results on a new benchmark of multi-step drug discovery tasks.

  13. YAC: Bridging Natural Language and Interactive Visual Exploration with Generative AI for Biomedical Data Discovery

    cs.HC 2025-09 unverdicted novelty 5.0

    YAC is a prototype system that uses a tool-calling multi-agent architecture to translate natural language into linked interactive visualizations and filters for biomedical data, with user-adjustable structured output ...

  14. The Path to Self-Evolving Clinical Systems: Scaling Medical Agents from Assistance to Autonomy

    cs.AI 2026-07 conditional novelty 4.5

    Medical agents should be scaled mainly by richer clinical environments and self-evolution loops, not parameter growth alone, under a three-level autonomy taxonomy.

  15. Vibe Medicine: Redefining Biomedical Research Through Human-AI Co-Work

    cs.AI 2026-04 unverdicted novelty 4.0

    Vibe Medicine proposes directing AI agents via natural language for end-to-end biomedical workflows using LLMs, agent frameworks, and a curated collection of over 1,000 medical skills.